SL Moulder

1.2k total citations · 1 hit paper
16 papers, 814 citations indexed

About

SL Moulder is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, SL Moulder has authored 16 papers receiving a total of 814 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in SL Moulder's work include Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (7 papers) and Peptidase Inhibition and Analysis (3 papers). SL Moulder is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Advanced Breast Cancer Therapies (7 papers) and Peptidase Inhibition and Analysis (3 papers). SL Moulder collaborates with scholars based in United States, Canada and Spain. SL Moulder's co-authors include JT Chang, Mustafa Khasraw, Daniel J. McGrail, Naoto T. Ueno, JK Litton, Maarten Slagter, S.-Y. Lin, Eric Jonasch, Leonie Voorwerk and Bora Lim and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

SL Moulder

15 papers receiving 812 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types

2021 672 citations Daniel J. McGrail, Leonie Voorwerk et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
SL Moulder United States	8	620	354	243	202	180	16	814
JK Litton United States	5	536 0.9×	295 0.8×	238 1.0×	198 1.0×	175 1.0×	19	733
JT Chang United States	2	497 0.8×	281 0.8×	215 0.9×	193 1.0×	152 0.8×	5	689
Leonie Voorwerk Netherlands	10	743 1.2×	338 1.0×	298 1.2×	350 1.7×	238 1.3×	17	1.0k
Hao-Ran Zhai China	5	601 1.0×	538 1.5×	237 1.0×	141 0.7×	245 1.4×	14	838
Zhanhong Xie China	18	761 1.2×	519 1.5×	172 0.7×	164 0.8×	227 1.3×	60	1.1k
G. Celine Han United States	9	415 0.7×	345 1.0×	151 0.6×	169 0.8×	190 1.1×	17	730
Mariacarla Andreozzi Italy	10	607 1.0×	407 1.1×	150 0.6×	176 0.9×	177 1.0×	19	804
Youjin Kim South Korea	14	452 0.7×	444 1.3×	168 0.7×	101 0.5×	150 0.8×	28	689
Daniel Carvajal United States	4	931 1.5×	402 1.1×	111 0.5×	368 1.8×	91 0.5×	8	1.0k
Gabriele Minuti Italy	12	665 1.1×	515 1.5×	164 0.7×	119 0.6×	229 1.3×	35	911

Countries citing papers authored by SL Moulder

Since Specialization

Citations

This map shows the geographic impact of SL Moulder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SL Moulder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SL Moulder more than expected).

Fields of papers citing papers by SL Moulder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SL Moulder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SL Moulder. The network helps show where SL Moulder may publish in the future.

Co-authorship network of co-authors of SL Moulder

This figure shows the co-authorship network connecting the top 25 collaborators of SL Moulder. A scholar is included among the top collaborators of SL Moulder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SL Moulder. SL Moulder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

McGrail, Daniel J., Leonie Voorwerk, Maarten Slagter, et al.. (2021). High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of Oncology. 32(5). 661–672. 672 indexed citations breakdown →

Damodaran, Senthil, Funda Meric‐Bernstam, JK Litton, et al.. (2019). Abstract OT1-03-04: INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC). Cancer Research. 79(4_Supplement). OT1–3. 1 indexed citations

Yam, Clinton, Lumarie Santiago, JK Litton, et al.. (2018). Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer. Cancer Research. 78(4_Supplement). P6–3.

Gauthier, Eric, Chandrasekar Durairaj, Xin Huang, et al.. (2017). Abstract P4-22-10: Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc. Cancer Research. 77(4_Supplement). P4–22. 1 indexed citations

Raghavendra, Akshara Singareeka, et al.. (2017). Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer. Cancer Research. 77(4_Supplement). P4–21. 1 indexed citations

Hurvitz, SA, DA Yardley, Amelia Zelnak, et al.. (2017). Abstract OT2-01-05: TRINITI-1: Ribociclib + everolimus (EVE) + exemestane (EXE) triplet combination in men or postmenopausal women with HR+, HER2– advanced breast cancer (ABC) following progression on a cyclin-dependent kinase (CDK) 4/6 inhibitor. Cancer Research. 77(4_Supplement). OT2–1. 2 indexed citations

Hamilton, Erika, et al.. (2017). Abstract P4-21-01: Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+ metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets). Cancer Research. 77(4_Supplement). P4–21. 7 indexed citations

Finn, RS, Yuqiu Jiang, Hope S. Rugo, et al.. (2016). Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC). Annals of Oncology. 27. vi554–vi554. 46 indexed citations

Hamilton, E.P., SL Moulder, Nathalie Aucoin, et al.. (2016). Abstract P4-14-19: ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). Cancer Research. 76(4_Supplement). P4–14. 5 indexed citations

10.

Gilcrease, Michael Z., Thorunn Helgason, Funda Meric‐Bernstam, et al.. (2016). Abstract P3-14-02: Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer (TNBC): Evidence of efficacy and proof of concept from a phase I trial with dose expansion of mTOR inhibition in combination with liposomal doxorubicin and bevacizumab. Cancer Research. 76(4_Supplement). P3–14. 3 indexed citations

11.

Falchook, Gerald S., et al.. (2013). Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Annals of Oncology. 24(12). 3004–3011. 25 indexed citations

12.

Modi, Sagar, et al.. (2010). Abstract P3-14-02: Phase 1 Dose-Escalation Study of the Heat Shock Protein 90 Inhibitor BIIB021 with Trastuzumab in HER2+ Metastatic Breast Cancer. Cancer Research. 70(24_Supplement). P3–14. 11 indexed citations

13.

Moulder, SL, et al.. (2010). Abstract P3-14-07: A Phase 1 Study To Assess the Safety, Tolerability and PK of ARRY-380 — An Oral HER2 Inhibitor. Cancer Research. 70(24_Supplement). P3–14. 4 indexed citations

14.

Moulder, SL, Linda Hsu, Shu‐Wan Kau, et al.. (2008). Prognostic impact of discordance/concordance of triple-receptor expression between primary tumor and metastasis in patients with metastatic breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1001–1001. 7 indexed citations

15.

Stopeck, Alison, SL Moulder, Suzanne F. Jones, et al.. (2007). Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules. Journal of Clinical Oncology. 25(18_suppl). 2571–2571. 20 indexed citations

16.

Hong, David S., Luis H. Camacho, Chaan S. Ng, et al.. (2007). Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant UO1 CA062461). Journal of Clinical Oncology. 25(18_suppl). 3549–3549. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact